IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis

Amanda A. Watkins, Kei Yasuda, Gabriella E. Wilson, Tamar Aprahamian, Yao Xie, Elena Maganto-Garcia, Prachi Shukla, Lillian Oberlander, Bari Laskow, Hanni Menn-Josephy, Yuanyuan Wu, Pierre Duffau, Susan K. Fried, Andrew H. Lichtman, Ramon G. Bonegio, Ian R. Rifkin

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

Premature atherosclerosis is a severe complication of lupus and other systemic autoimmune disorders. Gain-of-function polymorphisms in IFN regulatory factor 5 (IRF5) are associated with an increased risk of developing lupus, and IRF5 deficiency in lupus mouse models ameliorates disease. However, whether IRF5 deficiency also protects against atherosclerosis development in lupus is not known. In this study, we addressed this question using the gld.apoE-/- mouse model. IRF5 deficiency markedly reduced lupus disease severity. Unexpectedly, despite the reduction in systemic immune activation, IRF5-deficient mice developed increased atherosclerosis and also exhibited metabolic dysregulation characterized by hyperlipidemia, increased adiposity, and insulin resistance. Levels of the atheroprotective cytokine IL-10 were reduced in aortae of IRF5-deficient mice, and in vitro studies demonstrated that IRF5 is required for IL-10 production downstream of TLR7 and TLR9 signaling in multiple immune cell types. Chimera studies showed that IRF5 deficiency in bone marrow-derived cells prevents lupus development and contributes in part to the increased atherosclerosis. Notably, IRF5 deficiency in non-bone marrow-derived cells also contributes to the increased atherosclerosis through the generation of hyperlipidemia and increased adiposity. Together, our results reveal a protective role for IRF5 in lupus-associated atherosclerosis that is mediated through the effects of IRF5 in both immune and nonimmune cells. These findings have implications for the proposed targeting of IRF5 in the treatment of autoimmune disease as global IRF5 inhibition may exacerbate cardiovascular disease in these patients.

Original languageEnglish
Pages (from-to)1467-1479
Number of pages13
JournalJournal of Immunology
Volume194
Issue number4
DOIs
StatePublished - 15 Feb 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis'. Together they form a unique fingerprint.

Cite this